BioSpace News Archive

IMRIS, Deerfield Imaging, global leaders in the hybrid operating room market, announced today that Memorial Sloan Kettering Cancer Center signed a formal agreement to design and build a new IMRIS Surgical Theatre at their New York City location.

MJardin Group, Inc. (“MJardin” or the “Company”) (CSE:MJAR), a leader in cannabis management, today announced that it will release financial results for its third quarter ended September 30, 2018 before the stock market opens on Wednesday, November 28, 2018.

A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends Jardiance® (empagliflozin) as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference which takes place November 27-29 in New York, NY.

“I suffer from back pain,” said an inventor from Lauderhill, Fla. “This inspired me to develop an easy to use and store device that would alleviate this pain.”

Rocket (Nasdaq:RCKT), a leading U.S.-based multi-platform gene therapy company, andREGENXBIO (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an exclusive, worldwide license agreement for Rocket to develop and commercialize gene therapy treatments for Danon disease

The first-in-human Phase 1 study is evaluating the safety and efficacy of DNX-2440 to patients with recurrent glioblastoma for whom surgery is not possible or planned.

Perrigo Company (NYSE; TASE: PRGO) today announced it has received tentative approval from the Food and Drug Administration (FDA) for the first to file generic version of Ultravate® Lotion (halobetasol propionate) 0.05%.

The actor advocates for his son and others affected by epilepsy

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced an agreement with Puration, Inc. (USOTC: PURA) to develop and produce NuGenerex CBD HydroHealth High Alkaline Water.